- • Accelerate your promising therapeutic to market
- • Ensure accurate CMC submissions
- • Comply with emerging regulatory expectations
- • Apply best practices from leading preclinical/clinical projects
- • Improve process development timelines
This year, we move coasts and provide you visionary keynotes sharing key success factors for drug development and manufacturing highlighting these areas:
- >Antisense Technology: Stanley T. Crooke, Ph.D., Chief Executive Officer, Isis Pharmaceuticals, Inc.
- >RNAi Therapeutics: John Maraganore, Ph.D., Chief Executive Officer, Alnylam Pharmaceuticals
- >Peptide Therapeutics: Torsten Hoffmann, Ph.D., Executive VP and CSO, Zealand Pharma A/S
- >Oral Peptide: Kunwar Shailubhai, Ph.D., Co-Founder & CSO, Synergy Pharmaceuticals, Inc.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment